RLMD
Relmada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.43
+1.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- +7.6%
- EPS
- +58.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +30.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +28.3%
- EBIT
- +29.6%
- Net income
- +28.3%
- EPS
- +45.3%
- Free cash flow
- +11.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026